HaystackAnalytics, an Indian health-tech startup, supported by the Department of Science & Technology, Govt of India, healthcare veterans like Dr Velumani, and private players such as GE Healthcare and Intel, has developed the first of its kind Universal Infectious Diseases (ID) Test in the country, that deploys Next-Generation Sequencing (NGS) technology to identify existing and emerging infections, while providing information on drug resistance to support and identify correct treatment options for patients.

HaystackAnalytics has partnered with various diagnostic centers such as Unipath, Anderson, Sterling Accuris, Apollo Hospitals and over 20+ hospitals including AIIMS, to introduce their Sequencing based clinical products for TB and COVID-19 in the past. The new Universal Infectious Diseases test developed by HaystackAnalytics will be rolled out with their current partners in a phased manner over the next three months, and will be initially targeted at identifying and treating sepsis in Intensive Care Unit (ICU) patients, but gradually be made available to anyone suffering from a fever of unknown origin, by eradicating the need to conduct multiple tests.

The Universal Infectious Diseases (UID) test  developed by HaystackAnalytics, comes at an opportune time, as the learnings from the Covid-19 pandemic highlight the need for better diagnostic technologies, appropriate antibiotic use, and the renewed importance of infection prevention strategies.

HaystackAnalytics is building an all encompassing platform for healthcare, and has already introduced a game-changing TB test which is being used for accurate diagnosis of tuberculosis in India, yet another life threatening disease which claimed over 4.5 lakhs deaths in 2019.